Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis.

Eur Heart J Open · 2025 · PMC12637029 · PMID 41282536

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

approached significanceno p-value reported

For the primary endpoint, tafamidis and vutrisiran demonstrated a significant survival benefit over placebo; acoramidis approached significance.

also in 8,237 other papers

showed a trendno p-value reported

Tafamidis showed the greatest relative reduction in the occurrence of the primary outcome as compared to placebo (HR 0.69, 95% CrI from 0.53 to 0.88), followed by vutrisiran monotherapy (HR 0.74, 95% CrI from 0.58 to 0.91); acoramidis showed a trend towards benefit as compared to placebo (HR 0.76, 95% CrI from 0.56 to 1.03).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.